AmeriCare Home Health has been acquired by Brooks Rehabilitation
The private shareholders of AmeriCare Home Health (AmeriCare) have sold the company to Brooks Rehabilitation. Financial details have not been disclosed.
AmeriCare is a leading provider of home healthcare services including skilled nursing, physical therapy, occupational therapy, speech therapy, social work, home health aide, and private duty. The company is headquartered in Jacksonville, Florida, and operates 10 satellite office locations serving 23 counties in northeast and central Florida.
Brooks Rehabilitation is a recognized leader in providing a system of world class rehabilitation services. It operates an inpatient hospital providing rehabilitation and medical care for people requiring intensive inpatient therapy, 26 outpatient clinics, as well as Brooks Home Care which serves northeast Florida.
Oaklins' team in Jacksonville acted as financial advisor and intermediary to the seller in this transaction.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more